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High burden of complicated skin and soft
tissue infections in the Indigenous
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dominant Panton Valentine leucocidin
clones ST93-MRSA and CC121-MSSA
Susan A.J. Harch1,4*, Eleanor MacMorran1, Steven Y.C. Tong2,5, Deborah C. Holt2, Judith Wilson2, Eugene Athan3
and Saliya Hewagama1
Abstract
Background: Superficial skin and soft tissue infections (SSTIs) are common among the Indigenous population
of the desert regions of Central Australia. However, the overall burden of disease and molecular epidemiology
of Staphylococcus aureus complicated SSTIs has yet to be described in this unique population.
Methods: Alice Springs Hospital (ASH) admission data was interrogated to establish the population incidence
of SSTIs. A prospective observational study was conducted on a subset of S. aureus complicated SSTIs (carbuncles
and furuncles requiring surgical intervention) presenting during a one month period to further characterize the
clinical and molecular epidemiology. High resolution melting analysis was used for clonal complex discrimination.
Real-time polymerase chain reaction identifying the lukF component of the Panton Valentine leucocidin (pvl)
gene determined pvl status. Clinical and outcome data was obtained from the ASH medical and Northern
Territory shared electronic health records.
Results: SSTIs represented 2.1% of ASH admissions during 2014. 82.6% occurred in Indigenous patients (n = 382)
with an estimated incidence of 18.9 per 1, 000 people years compared to the non-Indigenous population of 2.9
per 1000, with an incident rate ratio of 6.6 (95% confidence interval 5.1–8.5). Clinical and molecular analysis was
performed on 50 isolates from 47 patients. Community-associated methicillin-resistant S. aureus (CA-MRSA)
predominated (57% of isolates). The high burden of SSTIs is partly explained by the prevalence of pvl positive
strains of S. aureus (90% isolates) for both CA-MRSA and methicillin-susceptible S. aureus (MSSA). ST93-MRSA and
CC121-MSSA were the most prevalent clones. SSTIs due to ST93-MRSA were more likely to require further
debridement (p = 0.039), however they also more frequently received inactive antimicrobial therapy (p < 0.001).
Conclusions: ST93-MRSA and CC121-MSSA are the dominant causes of carbuncles and furuncles in Central
Australia. Both of these virulent clones harbor pvl but the impact on clinical outcomes remains uncertain. The
high prevalence of CA-MRSA supports empiric vancomycin use in this population when antimicrobial therapy is
indicated. Prompt surgical intervention remains the cornerstone of treatment.
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Background
Indigenous populations worldwide suffer from a high
burden of infectious diseases. As with Indigenous popu-
lations elsewhere, Indigenous Australians of Central
Australia share many of the same issues of remoteness,
overcrowding, poverty and poor access to sanitation and
health care [1–3].
Skin and soft tissue infections (SSTIs) are observed to
be extremely common within the Indigenous population
of Central Australia. The combination of socioeconomic
disadvantage, high rates of communicable infections
such as scabies and non-communicable diseases inclu-
ding diabetes mellitus provide a highly vulnerable host
for SSTIs [2, 3]. Staphylococcus aureus infection is
responsible for significant morbidity and mortality
amongst this population, with SSTIs the leading cause
of S. aureus bacteraemia [4] and frequently associated
with prolonged hospital admissions for wound care
with subsequent community dislocation. Despite this,
the burden of disease due to superficial SSTIs in the
Central Australian Indigenous population has not pre-
viously been investigated.
Community-associated methicillin-resistant S. aureus
(CA-MRSA) and Panton Valentine leucocidin (PVL)
positive infection are prevalent and seemingly on the
increase in regional studies on S. aureus bacteraemia
[4–7]. The rise of this S. aureus phenotype may be
contributing to the burden of SSTIs related disease
[8]. While the molecular epidemiology of S. aureus
has been described in Indigenous Australians in tro-
pical northern Australia [9], data on the circulating S.
aureus clones associated with SSTIs is lacking for the
geographically and ethnically distinct desert regions of
Central Australia. Furthermore, the correlates between
the molecular epidemiology and clinical characteristics
including outcomes of complicated S. aureus SSTIs is
unknown.
Additionally, the prevalence of a newly defined species,
S. argenteus [10] has not been established. This is of
interest as S. argenteus, formerly known as S. aureus
CC75, is common in the Indigenous population of tro-
pical northern Australia [11].
Methods
Alice Springs Hospital (ASH) is the sole hospital provi-
ding tertiary health services for Central Australia, a
population of approximately 60, 000 over a catchment
area of 1.6 million square kilometers [12]. The catch-
ment region is predominantly within the Northern Ter-
ritory but also extends into Western Australia, South
Australia and Queensland. Approximately 44% of the
population identify as Indigenous but represent over
70% of ASH inpatients.
Data pertaining to the Diagnosis-Related Group (DRG)
‘cellulitis, boil, furuncle, carbuncle and abscess’ for the
calendar year 2014 at ASH was queried to establish the
incidence of hospital admissions due to SSTIs [13].
Australian Bureau of Statistics (ABS) population data [14]
was utilised to calculate the regional incidence of SSTIs.
The ABS estimate the total population for the Alice
Springs, Barkly, Central Desert and MacDonnell Local
Government Areas to be 48, 079 persons, with 20,262 per-
sons identifying as Indigenous and 27,817 persons identi-
fying as non-Indigenous [14].
We conducted a prospective, observational cohort
study of a subset of patients presenting to ASH with a
complicated, abscess related SSTI during a 1 month
period (October 2014). We identified cases via operating
theatre lists and included patients with: (1) spontaneous
SSTI due to a carbuncle or furuncle, (2) surgical inter-
vention required, and (3) available S. aureus isolate. Ex-
clusion criteria were: (1) secondary infection related to a
wound, and (2) polymicrobial infections.
We obtained microbiological cultures from routine clin-
ical specimens, with preference for surgical specimens. S.
aureus was identified by routine laboratory protocols
(morphology, catalase and Staphaurex tests (Oxoid, 2011)),
with organism confirmation and antimicrobial susceptibility
testing performed on the Vitek 2 (Biomerieux, version 7.01)
using the Clinical Laboratory Standards Institute M100-S24
Performance Standards. We used real-time polymerase
chain reaction (PCR) to detect the presence of the nucA,
mecA and lukSF genes to determine the status of S. aureus,
methicillin-resistance and PVL respectively. High resolution
melting (HRM) analysis in conjunction with real-time PCR
was used to discriminate the different clonal complexes
[15]. We used ST93 rather than CC93 for those inferred to
be ST93, as ST93 is a singleton sequence type with no iden-
tified related sequence types in the MLST database. We de-
fined CA-MRSA as resistant to <3 non β–lactam antibiotic
classes, and multi-resistant MRSA (mMRSA) as resistant to
≥3 non β–lactam antibiotic classes. Clinical data of cases
was obtained from ASH medical records and included
demographics, co-morbidities, recent hospitalization, infec-
tion, treatment and outcome data.
We analyzed differences between clonal types, clinical
and outcome data using Analysis of Variance for con-
tinuous data and Fisher’s exact test for categorical va-
riables in R version 3. 1. 2 (R Development Core Team
2014). Incident rate ratios were calculated in Stata ver-
sion 14.2 (StataCorp, College Station, Texas).
Ethics approval was granted by the Central Australian
Human Research Ethics Committee (HREC-14-223).
Results
Skin and soft tissue infections represented by the DRG
code ‘cellulitis, boil, furuncle, carbuncle and abscess’
Harch et al. BMC Infectious Diseases  (2017) 17:405 Page 2 of 7
constituted 2.1% of all ASH admissions during 2014.
Consistent with previous years, it was the most frequent
reason for admission under the General Surgical Unit.
Overall, there were 462 ASH admissions attributed to
SSTIs with the majority occurring in Indigenous patients
(n = 382, 82.6%). The estimated incidence of SSTIs
within the Indigenous population was 18.9 per 1, 000
people years and within the non-Indigenous population
was 2.9 per 1, 000 people years, within an incident rate
ratio of 6.6 (95% confidence interval 5.1–8.5).
Forty-nine cases for the prospective, observational
cohort study were identified following screening and
application of exclusion criteria. Most identified as
Indigenous (90%), median age was 30 years and approxi-
mately 60% were female (Table 1). Despite the young
population age, comorbidities with diabetes mellitus
(50%), chronic kidney disease (25%), obesity (27%) and
scabies infection (25%) were common. Almost half (49%)
the population lived in remote communities.
All cases had community onset disease, 36.7% had
been admitted to ASH in the preceding 6 months and
38% had CA-MRSA previously isolated (clinical or
screening specimens). CA-MRSA was the predominant
phenotype (57%). Many patients received inactive empi-
rical antimicrobial therapy (36.7%) prior to surgical
intervention. The most frequently prescribed empiric
antimicrobials were flucloxacillin (50%), vancomycin
(20%) and cephazolin (14%). Surgical intervention was
generally performed within 1 day of admission. Blood
cultures were obtained in 16 cases (33%) and were posi-
tive for MSSA in just one instance.
Clonal complex and pvl status was successfully deter-
mined for 50 isolates from 47 patients. Eight clonal com-
plexes were identified (Table 2). The clonal complexes
with the highest frequency were ST93 (48%) and CC121
(30%). Of the paired isolates, one case had two MSSA
strain types (CC5 and CC121) and two cases had con-
current MSSA and CA-MRSA strain types (CC5 and
CC8, and CC1 and ST93). pvl positive disease domi-
nated the cohort with 90% of isolates carrying the lukSF
gene, occurring in both MSSA and CA-MRSA isolates
and across all clonal complexes except for CC1 and
CC88. S. argenteus was not identified.
There was clear correlation between clones and anti-
microbial phenotype. The majority of ST93 isolates were
CA-MRSA (96%), whilst all CC121 isolates were MSSA
(p < 0.001). 60% of CC121 isolates were resistant to
clindamycin, compared to 12.5% of ST93 isolates being
clindamycin resistant (p = 0.006). Trimethoprim/ sulfa-
methoxazole resistance occurred in two pvl positive CC5
isolates (4%).
There were some differences between S. aureus clones
and clinical variables (Table 1). On univariate analysis,
infections due to ST93 were more likely to require
further debridement (p = 0.039) but this group also
more frequently received inactive antimicrobial therapy
prior to debridement (p < 0.001).
Discussion
Key findings of this study include the very large burden
of SSTIs experienced in Central Australia and the vast
disparity between Indigenous and non-Indigenous
Australians. The incidence of SSTIs requiring hospitali-
sation within the Indigenous population of Central
Australia is estimated to be 18.8 per 1000 people years.
This is almost seven times the incidence for the local
non-Indigenous population. More concerning, the inci-
dence is over 30 times the estimated national Australian
hospitalisation rate for cutaneous abscesses of 62 per
100, 000 people years [16]. Moreover the incidence is
significantly higher than other developed nations, with
an American retrospective survey describing an inpatient
admission SSTI incidence of 2.19 per 1, 000 person
years [8].
There continues to be a rise in CA-MRSA particularly
within Australian Indigenous communities [7] and our
study reflects this trend. We have demonstrated that
CA-MRSA is now the dominant S. aureus phenotype in
carbuncle and furuncle related SSTIs in the desert re-
gions of Central Australia. The prevalence of CA-MRSA
in this SSTI subset (57%) well exceeds the prevalence
rates of approximately 20% described in previous
Australian S. aureus studies [6, 7, 17]. CA-MRSA is in-
creasingly responsible for SSTIs in Australian Indigen-
ous populations, and in particular the dominant ST93-
MRSA clone has continued its spread within Australia
into the desert regions of Central Australia. MSSA
continues to contribute substantially to the burden of
carbuncle and furuncle related SSTIs with CC121 the
major MSSA clone. Notably, both ST93 and CC121 are
pvl positive clones.
Despite the geographic isolation, high Indigenous popu-
lation and substantial burden of disease, the molecular
epidemiology of SSTI isolates in Central Australia had a
number of similarities to other Australian regions. Clonal
diversity is a unique feature of S. aureus in Australia, with
a recent prevalence survey identifying more than 30
clones in CA-MRSA alone [17]. There are six major
MRSA clones including ST93-IV, ST30-IV, ST1-IV,
ST45-V, ST78-IV and ST5-IV [17]. ST93 is notable
for causing abundant [9, 17, 18] and possibly more
virulent disease in Australia [19] . We also observed
significant clonal diversity with 8 clonal complexes
identified within 50 isolates, including CC1, CC5,
CC8, CC22, CC30, ST93, CC121 and CC88.
Like other regions in Australia, we observed ST93 to
be the most frequent strain (48%) and strongly asso-
ciated with CA-MRSA (96%). ST93 has been found to
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Table 1 Correlation of clinical variables and S. aureus clonal complexes
Variable Overall n = 49
n (%a), median (IQR)
At least one isolate
ST93 n = 24
n (%), median (IQR)
At least one isolate
CC121 n = 15
n (%), median (IQR)
Other clonal
complexes n = 10
n (%), median (IQR)
Demographics
Ethnicity: Indigenous 44 (89.8) 22 (91.7) 14 (93.3) 8 (80.0)
Gender: Female 29 (59.2) 12 (50.0) 9 (60.0) 8 (80.0)
Age (years) 30.0 [10.0, 46.0] 28.5 [11.2, 47.0] 34.0 [24.5, 45.5] 20.5 [4.5, 42.2]
Residence
Town camp 12 (24.5) 6 (25.0) 4 (26.7) 2 (20.0)
Remote community 24 (49.0) 12 (50.0) 6 (40.0) 6 (60.0)
Prison 1 (2.0) 1 (6.7)
Visitor 2 (4.1) 1 (4.2) 1 (10.0)
House in Alice Springs 10 (20.4) 5 (20.8) 4 (26.7) 1 (10.0)
Co-morbidities
Diabetes mellitus 22 (44.9) 12 (50.0) 6 (40.0) 4 (40.0)
Chronic kidney disease 12 (24.5) 6 (25.0) 3 (20.0) 3 (30.0)
Haemodialysis 2 (4.1) 2 (8.3) 0 (0.0) 0 (0.0)
Excess alcohol use 6 (12.2) 3 (12.5) 2 (13.3) 1 (10.0)
Obesity (BMI ≥ 30) 13 (26.5) 3 (12.5) 7 (46.7) 3 (30.0)
Cardiac failure 6 (12.2) 2 (8.3) 3 (20.0) 1 (10.0)
Ischaemic heart disease 4 (8.2) 2 (8.3) 1 (6.7) 1 (10.0)
Scabies 12 (24.5) 5 (20.8) 4 (26.7) 3 (30.0)
Asthma 5 (10.2) 1 (4.2) 1 (6.7) 3 (30.0)
Healthcare exposure
Admission in previous 6 months 18 (38.3) 9 (39.1) 5 (33.3) 4 (44.4)
Previous CA- MRSA 18 (38.3) 10 (43.5) 3 (20.0) 5 (55.6)
Clinical presentation
Size (cm) 4.0 [3.0, 5.0] 4.0 [2.5, 5.0] 4.0 [3.0, 6.0] 5.5 [3.5, 9.0]
Duration (days) 5.0 [2.0, 7.0] 5.5 [3.2, 7.0] 4.0 [2.0, 6.5] 3.0 [2.0, 7.0]
Site of infection
Head & neck 8 (16.3) 5 (20.8) 3 (20.0)
Upper limb 9 (18.4) 7 (29.2) 1 (6.7) 1 (10.0)
Torso 6 (12.2) 3 (12.5) 13.3 (2)
Buttock/groin/thigh 12 (24.5) 6 (25.0) 2 (13.3) 1 (10.0)
Lower leg 11 (22.4) 2 (8.3) 26.7 (4) 3 (30.0)
Multiple 3 (6.1) 1 (4.2) 13.3 (2) 5 (50.0)
Treatment
Time to surgery (days) 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0]
Antimicrobials prior surgery
Inactive 18 (36.7) 13 (54.2) 5 (50.0)
Active 30 (61.2) 10 (41.7) 15 (100.0) 5 (50.0)
Planned oral antibiotic duration (days) 7.0 [2.0, 7.0] 6.5 [3.2, 7.0] 5.0 [0.0, 7.0] 7.0 [5.5, 7.0]
Clinical outcomes
Length of stay (days) 3.0 [2.0, 7.0] 3.0 [3.0, 6.0] 2.0 [2.0, 6.5] 3.0 [2.2, 7.0]
Progression to deep structures 5 (11.9) 3 (15.0) 0 (0.0) 2 (25.0)
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hyperexpress the exotoxin α-haemolysin which enhances
the virulence of the clone, particularly in SSTIs [20].
The high virulence and expression of α-haemolysin in
ST93 may be a driving factor in the substantial burden
of disease seen in Central Australia [19–21].
Following ST93, the next major clone was CC121
(30%), which was exclusively methicillin-susceptible. The
association of CC121 with SSTI is consistent with the
international literature and CC121 is phenotypically
usually MSSA [22]. The molecular epidemiology of
MSSA infections has been studied in less detail than
CA-MRSA [23], but CC121 is commonly associated with
SSTIs in Australia. However, the high prevalence of
CC121 in our study (30%) is greater than that reported
elsewhere in the Northern Territory ‘Top End’ and
metropolitan centers [9, 18], and may be a unique fea-
ture of the Central Australian region.
The absence of S. argenteus is an interesting finding
of this study and key difference to other Australian
regions. S. argenteus was initially reported in the
Northern Territory ‘Top End’ [9, 24], but it is now
clear it has a global distribution [10]. The clinical
niche of S. argenteus appears to differ from S. aureus
[21]. S. argenteus may have less of a predilection to
cause abscesses and furuncles and further studies of non-
complicated SSTI will be required to determine whether
S. argenteus is truly absent from Central Australia.
The dominance of pvl positive S. aureus isolates (90%)
may be contributing to the very high incidence of ab-
scess related SSTIs in Central Australia [9] and is not-
able for two reasons. Firstly, it was widespread in both
MSSA and CA-MRSA isolates. The association between
PVL and abscess related SSTIs is well described [25],
however the prevalence of pvl in our cohort was sub-
stantially higher than in other Australian urban settings
(MSSA 15%, CA-MRSA 42%) [18] and the Northern
Territory Top End (MSSA 40%, CA-MRSA 54%). Se-
condly, the presence of pvl appears to have limited
impact on clinical outcomes following surgical interven-
tion. Controversy continues regarding the pathogenic
role of PVL, with laboratory and animal model data sug-
gesting it is not a major virulence factor [26, 27]. In our
study, detailed clinical outcome comparisons were li-
mited by the small number of pvl negative cases (10%).
Despite this, most patients achieved good clinical out-
comes with only one episode of bacteraemia and a mi-
nority experiencing progression to deep tissue structures
(12%) and secondary infection (2.5%). It was not possible
to determine if these complications were related to the
presence of pvl or a delay in presentation to health-
services or poor wound care upon discharge. Therefore,
we believe the typical rapid response to surgical inter-
vention observed in our study provides further support
to the findings of Shallcross et al. that provided ‘appro-
priate surgical treatment and the correct antibiotics’ are
received, PVL appears to have little impact on clinical
outcomes [25].
Patients with CA-MRSA frequently received inactive
empiric antimicrobial therapy with antibiotic prescrip-
tion often in accordance with the Australian Therapeutic
Guidelines recommendation of di/flucloxacillin for em-
pirical therapy [28]. It follows then that infections due to
ST93 were more likely to receive inactive antimicrobials
compared to CC121 related infections (54.2% vs 100%,
Table 1 Correlation of clinical variables and S. aureus clonal complexes (Continued)
Secondary infection 1 (2.5) 0 (0.0) 1 (7.7) 0 (0.0)
Return to theatre 6 (12.5) 6 (26.1) 0 (0.0) 0 (0.0)
Readmission within 30 days 4 (8.3) 2 (8.7) 2 (13.3) 0 (0.0)
Unscheduled medical review 8 (21.1) 4 (23.5) 2 (15.4) 2 (25.0)
Repeat antibiotics required 10 (26.3) 3 (17.6) 6 (46.2) 1 (12.5)
Antimicrobial susceptibility
Methicillin resistance 28 (57.1) 23 (95.8) 0 (0.0) 5 (50.0)
Clindamycin resistance 3 (12.5) 9 (60.0)
Trimethoprim/sulfamethoxazole resistance 0 (0.0) 0 (0.0)
aCalculation of percentages takes into account missing data points
Table 2 S. aureus isolates: Frequency of clonal complexes and
carriage of pvl and mecA genes
Clonal complex
n (%)
pvl positive
n (%)
mecA positive
n (%)
Overall (n = 50) 45 (90.0) 28 (56.0)
CC1 1 (2.0) 0 (0) 0 (0)
CC5 4 (8.0) 3 (75.0) 3 (75.0)
CC8 3 (6.0) 1 (33.3) 1 (33.3)
CC22 1 (2.0) 1 (100.0) 0 (0)
CC30 1 (2.0) 1 (100.0) 1 (100.0)
ST93 24 (48.0) 24 (100.0) 23 (95.8)
CC121 15 (30. 0) 15 (100.0) 0 (0)
CC88 1 (2.0) 0 (0) 0 (0)
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p < 0.001). More importantly, all cases requiring further
debridement (n = 6) were ST93 (p = 0.039) and 50% of
these received inactive empiric antimicrobials. The high
rates of CA-MRSA and potential impact on clinical
outcomes lead us now to recommend the empiric use
of vancomycin for patients in Central Australia pre-
senting with SSTIs requiring surgical management.
Trimethoprim-sulfamethoxazole may be a preferred
empiric oral agent given the high rates of observed
clindamycin resistance (32%) and dosing ease.
Associations between clonal complexes and antibio-
grams were noteworthy. Clindamycin resistance occurred
in 32% of isolates, substantially higher than previous stu-
dies [17]. There was also a significant difference in clinda-
mycin resistance between the major strains CC121 (60%)
and ST93 (12.5%), p = 0.006. The impact on antimicrobial
prescribing is attenuated by CC121 isolates being exclu-
sively MSSA but this highlights the evolution to a more
broadly resistance antibiogram. The rise in clindamycin
resistance may be driven by high use of macrolide anti-
biotics in Indigenous communities of Central Australia,
typically indicated for Chlamydia trachomatis or chronic
suppurative lung disease.
There are now reports of resistance to trimethoprim-
sulfamethoxazole in CC5 strains from Indigenous com-
munities in the neighboring jurisdiction of Western
Australia [29]. We found two CC5 trimethoprim-
sulfamethoxazole resistant MRSA strains that were also
pvl positive. Therefore, ongoing surveillance for changes
in resistance and clonal patterns of S. aureus are re-
quired to update prescribing recommendations.
This study is limited by its observational design with
reliance on coding data to determine SSTI incidence
rates and retrieval of clinical data from medical records.
It was not possible to obtain ABS population data for
the entire ASH catchment given it includes partial Local
Government Areas of Western Australia, South
Australia and Queensland. Consequently, the population
incidence rate may be overestimated. Correlation of the
estimated ASH catchment population of 60, 000 with
44% identifying as Indigenous determines an incidence
of SSTIs within the Indigenous population as 14.5 per 1,
000 people years and within the non-Indigenous popula-
tion as 2.4 per 1000 people years.
The small sample size of cases, microbiological isolates
and patients with PVL negative disease is the major limi-
tation of this study and prevented detailed molecular
and clinical correlations. Similarly, our sampling oc-
curred over 1 month and if seasonal variation was
present, we would not have identified this. Review of
the geographic distribution of clonal complexes was
not possible due to use of broad residential categories
and the highly mobile nature of the local Indigenous
population. Given asymptomatic patients colonized
with pvl positive S. aureus were not included, associa-
tions with pvl positivity and clinical disease are only
epidemiological in nature and not causal. Other recog-
nized S. aureus virulence factors such as α-haemolysin
were not assessed.
Conclusions
In conclusion, we observed extremely high rates of com-
plicated SSTIs requiring hospitalization in Central
Australia, with the Indigenous population disproportio-
nately affected. Detailed review of the molecular epi-
demiology of carbuncle and furuncle related SSTIs
revealed the dominance of two clones ST93-MRSA and
CC121-MSSA. These two virulent clones both possess
the pvl gene but the impact of PVL toxin on clinical out-
comes remains uncertain. The prevalence of CA-MRSA
continues to rise locally, with significant ramifications for
antimicrobial prescribing. Empiric intravenous vanco-
mycin or oral trimethoprim-sulfamethoxazole is recom-
mended for this population when antimicrobial therapy is
indicated. Prompt surgical intervention remains the
cornerstone of treatment. Further studies correlating
clonal complex type, asymptomatic pvl carriage as well as
the presence of other virulence factors will help improve
our understanding of the pathogenesis of SSTIs.
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